Introduction
Cancer develops from an accumulation of genetic aberrations 1 . Particular genetic lesions may be essential for initiation and maintenance of particular cancers. Inducible transgenic models demonstrate that sustained activation of C-MYC is essential both for the establishment and continual growth of T cell lymphomas, myeloid leukemias, and osteogenic sarcomas 2, 3 . In human cancer cells at the time of diagnosis, the presence of multiple genetic defects usually prevents the identification of signaling pathways and cellular changes directly altered by the primary genetic lesion.
In over 90% of Chronic Myelogenous Leukemia (CML) cases, the initial genetic aberration is the Philadelphia chromosome (Ph+), which results from a reciprocal translocation between chromosome 9 within the tyrosine kinase gene ABL and chromosome 22 within the BCR gene 4, 5 . This creates a fusion gene product BCR-ABL [6] [7] [8] [9] [10] [11] . The deregulated tyrosine kinase activity of BCR-ABL is required to transform cells in vitro 12 and to generate a CML-like disease in vivo 13, 14 . Inhibition of BCR-ABL's tyrosine kinase activity with the drug STI571 (Gleevec, Imatinib mesylate) is sufficient to suppress CML in patients [15] [16] [17] and relapses from therapy are due to reactivation of BCR-ABL via mutation or amplification of the gene 18, 19 .
These results demonstrate that the BCR-ABL oncogene is required both for establishment and maintenance of CML.
CML begins with a long 3-5 year chronic phase characterized by an expansion of progenitor and mature myeloid cells, mild anemia, and splenomegaly. This chronic phase transforms to an aggressive stage (blast crisis) associated with numerous genetic abnormalities only.
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The cellular origin of CML begins with formation of the Ph+ in the hematopoietic stem cell (HSC) from where it is subsequently transmitted to all hematopoietic lineages 22, 23 . Studies of purified Ph+ HSCs suggest that either BCR-ABL is not expressed in this population 24 or it is insufficient to affect the quiescent status of HSCs 25 . Multipotent hematopoietic progenitors are receptive to BCR-ABL expression and generate an abnormal expansion of mature myeloid cells, a clinical feature of chronic phase CML 26, 27 . These results demonstrate that although the Ph+ originates in HSCs, multipotent hematopoietic progenitors and not HSCs are the cell population responding to BCR-ABL in CML.
Numerous signaling pathways regulated by BCR-ABL expression have been identified over the past decade, however their relevance towards the direct effect of BCR-ABL expression in multipotent hematopoietic progenitors remains unclear for two reasons. First, most BCR-ABL studies have been conducted in fibroblast, myeloid, and Pro-B cell lines, which do not represent multipotent hematopoietic progenitors 28 . Second, BCR-ABL studies conducted in the cellular context of hematopoietic progenitors have largely relied on the availability of CML patient materials. These studies could not distinguish direct BCR-ABL consequences versus other genetic and epigenetic effects that occurred during the evolution of these leukemic cells.
Alternative in vitro cellular systems have been developed that can be used to study BCR-ABL in the cellular context of hematopoietic progenitors. The pluripotent FDCP-Mix cell line
has been used to demonstrate that growth factor independence of myeloid cells requires longterm BCR-ABL expression 29 . Chronic BCR-ABL expression in human CD34+ multipotent progenitors via retroviral transduction delays apoptosis induced by serum and cytokine only.
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We have developed an ES in vitro differentiation system with tetracycline regulated BCR-ABL expression to study its effects during defined stages of hematopoietic differentiation 31 . BCR-ABL expression throughout in vitro hematopoiesis leads to an expansion of mature myeloid cells with a concomitant reduction in erythropoiesis mimicking some of the bone marrow features of chronic phase CML 31 .
In this study we determined which specific hematopoietic progenitor populations are responsive to initial BCR-ABL expression. Based on these results we propose a mechanism by which BCR-ABL expands such progenitors and the distinctive combination of signaling pathways that may be involved.
Materials and Methods

General maintenance of feeder-independent BCR-ABL inducible ES clones
ES clones 1-8 and 2-4, inducible for BCR-ABL expression via a tetracycline suppressible promoter were maintained as previously described 31, 32 .
Maintenance of OP9 stromal cell line
only.
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ES in vitro differentiation and induction of BCR-ABL expression during hematopoietic progenitor development
ES in vitro differentiation and induction of BCR-ABL expression was as previously described 31, 32 . Briefly, 10 4 undifferentiated ES cells, not induced for BCR-ABL expression, were co-cultured on a confluent OP9 stroma per well of a 6-well plate by adding 100ng/ml TET. For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From as per manufacturer's protocol (BD PharMingen, SD) and samples were analyzed using a FACScan (Becton Dickinson).
Retroviral vectors and generation of virus stocks
The retroviral vector pMSCV 33 containing either 5' LTR driven BCR-ABL P210 IRES EGFP or 5' LTR driven IRES EGFP were used to generate high-titer helper-free retrovirus stocks prepared by transient co-transfection of 293T cells 34 .
Generation of BCR-ABL expressing BaF3 cells and IL-3 stimulation
The IL-3-dependent BaF3 cell line was maintained in Ischove's medium supplemented with 10% FBS and 10% WEHI-3B conditioned medium (WEHI) as a source of IL-3. 
RT-PCR analyses
EGFP was used as a surrogate marker to sort for BCR-ABL expressing ES-differentiated day 7 hematopoietic progenitors to >95% purity using the FACSVantage cell sorter (Becton Dickinson). EGFP negative, BCR-ABL un-induced ES-differentiated day 7 hematopoietic progenitors was similarly purified. OP9 cells were harvested by trypsinization. Total RNA was extracted from 10 6 cells using the RNeasy Mini kit (Qiagen, CA) and 1ug of RNA was used to generate cDNA using SuperScript reverse transcriptase (Gibco-BRL) and oligo(dT) primer as per manufacturer's protocol. 1ul of cDNA was used per PCR reaction with SCF primers sense 
Protein analyses by Western Blotting
P-38 MAPK inhibition studies during ES-derived hematopoietic progenitor development
The P-38 MAPK specific inhibitor SB 203580 (559398) (Calbiochem Inc.) was added daily starting on day 5 of ES in vitro differentiation at concentrations of 0.1uM, 1uM, and 10uM.
An equivalent volume of DMSO was added to control cells. ES-day 7 differentiated hematopoieitic progenitors were harvested and evaluated for P-38 MAPK inhibitory effects.
Results
BCR-ABL expression at the onset of hematopoiesis expands multipotent and myeloid progenitors with suppression of differentiation into erythroblasts
We developed an ES in vitro differentiation system with tetracycline (TET) regulated BCR-ABL expression to study its effects during defined stages of hematopoietic differentiation 31, 32 . ES cells were induced to differentiate on an OP9 stromal cell line such that by day 5 of ES differentiation, the majority of cells were composed of mesodermal cells and hematopoietic precursors as defined by FLK-1 expression in 60-80% of the cells, VE-CADHERIN expression in 9-10% of the cells, and a lack of CD45 and Ter-119 expression ( Figure 1A only.
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We took advantage of multi-parameter cell surface marker analysis to define specific progenitor populations affected by BCR-ABL activation. C-KIT and CD34 receptors have been used in combination with lineage-depleted cells to define hematopoietic progenitors capable of in vivo multi-lineage reconstitution 40, 41 . This same set of markers was used to define multipotent hematopoietic progenitors in ES day 7 differentiated cells ( Figure 2B ). B and T cell progenitors
were not generated by day 7 of ES in vitro differentiation and erythroblasts did not express CD34
data not shown 31, 32, 38 . Consequently, most experiments utilized the myeloid specific CD11b integrin receptor as the sole marker for exclusion of lineage-committed progenitors from C-KIT and CD34 positive multipotent progenitors ( Figure 2B ). Lineage-committed myeloid progenitors were defined by co-expression of C-KIT and CD34 along with CD11b ( Figure 2B ).
Erythroblasts were identified by expression of Ter-119. This was sufficient to define erythroblasts because all day 7 ES cells contain a nucleus demonstrating that no mature
erythrocytes have yet formed ( Figure 2A ).
Short-term 48 Hours BCR-ABL expression expanded the total population of day 7 ES cells by 3.7-fold ( Figure 2C ). This BCR-ABL effect was dependent on its tyrosine kinase activity since addition of the inhibitor STI571 suppressed progenitor expansion ( Figure 2D ).
Specifically, BCR-ABL expression expanded multipotent and myeloid progenitors by 3.1-fold and 3.0-fold respectively ( Figure 2D ). The selective expansion of multipotent and myeloid progenitors could be due to a skewing of hematopoietic differentiation towards these cell types upon BCR-ABL induction. However, BCR-ABL expression did not increase the ratio of multipotent and myeloid progenitors generated ( Figure 2B ).
In contrast, BCR-ABL expression suppressed the development of erythroblasts with a 3.8-fold decrease in the percentage of erythroblasts generated ( Figure 2E ). This BCR-ABL only.
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SCF has been shown to synergize with BCR-ABL leading to an expansion of GM-CSF colonies 27 and erythroid cells [42] [43] [44] . The lack of BCR-ABL induced erythroid expansion in ES-OP9
cultures may be due to a lack of SCF production. By RT-PCR, OP9 cells and ES-derived hematopoietic progenitors express SCF ( Figure 1C and Figure 2 ) 45 . Addition of SCF from day 5
to day 7 of ES-OP9 differentiation did not lead to a further increase in any day 7 hematopoietic cell populations in the presence or absence of BCR-ABL expression (data not shown).
BCR-ABL expands hematopoietic progenitors by suppression of programmed cell death
In cell line studies BCR-ABL expression has been shown to expand cells by suppressing programmed cell death in the face of apoptosis inducing agents such as TNFα, etoposide, or growth factor withdrawal [46] [47] [48] . Primary Ph+ progenitors are also resistant to growth factor withdrawal induced cell death compared to normal progenitors 49 . However, Ph+ progenitors remain susceptible to TNFα, ceramide or irradiation-induced cell death [49] [50] [51] .
We next determined if BCR-ABL expression expanded ES-derived hematopoietic progenitors by suppressing programmed cell death in an environment without exogenous apoptotic stimuli. Previous analyses on the quantitative role of apoptosis following BCR-ABL only.
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Early stages of apoptosis were measured by analyzing the level of phosphatidylserine on cell surfaces via Annexin V staining. Cells already progressed to the stage of membrane integrity breakdown would leak out EGFP and were excluded by intercalation of 7AAD into their DNA. BCR-ABL expression suppressed apoptosis by three-fold, from 23% to 8% in ES- For only.
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BCL-X L may be a general anti-apoptotic molecule that contributes to BCR-ABL's ability to suppress cell death in different cell lineages.
BCR-ABL expression suppresses phosphorylation of P-38 MAPK at its Thr180-Gly-Tyr182 active site in hematopoietic progenitors
Inhibiting the expansion of Ph+ progenitors and cell lines with chemotherapeutic agents such as IFNα and butyrate correlates with phosphorylation of P-38 MAPK at its Thr180-GlyTyr182 active site 71, 72 . Addition of the P-38 MAPK specific inhibitor SB203580 is sufficient to restore in vitro expansion of Ph+ cells in the face of these chemotherapeutic agents 71, 72 . These results demonstrate that P-38 MAPK inhibition plays a critical role in the expansion of Ph+ cells.
Whether P-38 MAPK suppression is directly due to BCR-ABL expression or is an event that occurs during the evolution of a Ph+ leukemic clone has not been examined.
Acute BCR-ABL expression suppressed P-38 MAPK phosphorylation at its Thr180-GlyTyr182 active site in both ES-derived hematopoietic progenitors and BaF3 cells ( Figure 6A ).
The total amount of P-38 MAPK protein however, was significantly elevated upon BCR-ABL induction in ES-derived hematopoietic progenitors ( Figure 6A ). These results suggest that suppression of P-38 MAPK activation may prevent P-38 MAPK degradation leading to an accumulation of inactive P-38 MAPK in BCR-ABL expressing ES-derived hematopoietic progenitors.
Inhibition of P-38 MAPK activity expands hematopoietic progenitors by suppressing apoptosis analogous to BCR-ABL expression
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In ES-derived hematopoietic progenitors, 10uM SB203580 induced cell expansion by suppressing apoptosis from 21% to 7% as measured by Annexin V binding ( Figure 6C ). This three-fold reduction was of the same magnitude as BCR-ABL's level of apoptosis inhibition ( Figure 6C ). These results suggest that inhibition of the P-38 MAPK pathway can account for a remarkably large fraction of the overall anti-apoptotic effect mediated by BCR-ABL expression in ES-derived hematopoietic progenitors.
BCR-ABL suppresses P-38 MAPK activity and up regulates BCL-X L independent of each other
We examined whether inhibition of P-38 MAPK lead to an up regulation of BCL-X L as a possible mechanism for suppressing apoptosis in ES-derived hematopoietic progenitors.
Inhibition of P-38 MAPK with 10uM SB 203580 did not up regulate BCL-X L in the absence of BCR-ABL expression ( Figure 7 ). Furthermore, P-38 MAPK inhibition by SB 203580 did not lead to an accumulation of total P-38 MAPK unlike BCR-ABL expression ( Figure 7 ). Similar amounts of protein lysate were examined in each condition as verified by equal levels of total ERK 2 ( Figure 7 ). These results suggest that BCR-ABL induced suppression of P-38 MAPK activity and up regulation of BCL-X L occur independently of each other.
Discussion
We have examined the early effects of BCR-ABL expression on the growth and development of multi-lineage hematopoietic progenitors. Using a BCR-ABL inducible ES in vitro differentiation system we demonstrate that BCR-ABL expression selectively expands multipotent and myeloid progenitors with suppression of differentiation into erythroblasts.
These BCR-ABL effects require its tyrosine kinase activity and are independent of its reported scaffolding functions 75 . This suppression along the erythroid lineage is extended to a reduction in mature erythrocyte development in this system 31 . Together these results suggest that BCR-ABL expression may suppress hematopoietic development for the erythroid lineage leading to mild anemia in most CML patients. The Ph+ erythroblast K562 cell line requires BCR-ABL activity to suppress hemaglobinization providing further evidence to support this proposed mechanism 47 . However, BCR-ABL expression in CD34+ progenitors can exclusively lead to an increase in erythroid colonies [42] [43] [44] or GM-CSF colonies 26, 27 . Furthermore, EB derived BCR- 76 . These apparently conflicting results suggest that microenvironmental conditions such as stromal cell contacts and growth factor levels may play pivotal roles in determining the specific lineage of cells that BCR-ABL expression affects. In our ES-OP9 differentiation system, the micro-environment may be sufficient to support expansion of BCR-ABL expressing multipotent and myeloid progenitors and as a consequence, reduce the development of BCR-ABL expressing erythroblasts.
ABL hematopoietic progenitors exclusively develop into erythroid cells in vitro, but differentiate into myeloid, T and B cells in vivo
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The expansion of ES-derived multipotent and myeloid progenitors was mediated by a rapid anti-apoptotic effect and not by enhanced cell proliferation. Examining major antiapoptotic pathways connected to BCR-ABL expression from cell line studies revealed that AKT, STAT5 and BCL-2 were not up regulated upon BCR-ABL induction in ES-derived hematopoietic progenitors. In fact, STAT5 phosphorylation at its active site was undetectable in ES-derived hematopoietic progenitors. STAT5 has also been shown to be dispensable for generating a BCR-ABL induced myeloproliferative disorder in vivo 77 . These findings contrast with results from BCR-ABL expression in cell lines and highlight the importance of evaluating signaling in the specific cellular context of hematopoietic progenitors. ES in vitro differentiated progenitors can contribute to long-term, multi-lineage hematopoiesis in vivo 78 and BCR-ABL expressing ES-derived hematopoietic progenitor clones generate an acute leukemia in vivo 30 .
These results suggest that ES-derived hematopoietic progenitors may be a potential cell only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From BCR-ABL expression could suppress P-38 MAPK at different points along its activation pathway. We did not observe any diminution in the phosphorylation of its upstream kinase MKK3/6 (data not shown). P-38 MAPK phosphatases could be up regulated upon BCR-ABL induction. This is a difficult issue to examine because other MAPKs such as ERK and JNK can also be substrates for these phosphatases reviewed in 87 . BCR-ABL could also suppress TAB1 expression, a scaffolding protein that can bind to and auto-phosphorylate P-38 MAPK 88 .
Alternatively, P-38 MAPK suppression can occur upon RAS activation in fibroblasts 89 . BCR-ABL expression has been shown to increase the levels of active RAS-GTP 84 making this a likely pathway to be utilized by BCR-ABL for P-38 MAPK suppression.
We have shown that BCR-ABL expression suppresses P-38 MAPK activation in the face of IL-3 stimulation in BaF3 cells ( Figure 6A ). IL-3 is an activator of P-38 MAPK in BaF3 cells For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From and control day 7 ES-derived hematopoietic progenitors. CDNA was generated from these samples and PCR using SCF and HPRT specific primers were conducted. SCF primers would generate a 592bp cDNA fragment and ~1,500bp genomic band; HPRT primers would generate a 249bp cDNA fragment and ~1,100bp genomic band. Figure 6A and 6C with an additional total ERK2 antibody. These molecular pathways were analyzed from two independent experiments with similar results. only.
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